Conference Correspondent

Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Afatinib Improves Outcomes in Patients with Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent — September 30, 2014

Association of HPV and p16 Status with Cetuximab plus Radiotherapy in Locally Advanced Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent — September 30, 2014

Pembrolizumab in HPV-Positive Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent — September 30, 2014

Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent — September 30, 2014

Anti–PD-L1 Monoclonal Antibody MPDL3280A in Metastatic Urothelial Bladder Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Long-Term Follow-Up Results of MPDL3280A in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Page 36 of 44

33
34
35
36
37
38
39